Lupus Warriors on Capitol Hill: A Fight for Funding and Fair Access

WASHINGTON, D.C. – April 22, 2026 – The halls of Congress echoed with personal stories of struggle and resilience last week as hundreds of lupus advocates from 42 states convened for the Lupus Foundation of America's National Lupus Advocacy Summit. From April 19-21, patients, caregivers, and family members—dubbed “lupus warriors”—met with lawmakers to press for critical policy changes and increased federal funding for a disease that remains chronically misunderstood and under-researched.

Their timing was impeccable. The advocates arrived in the capital not just with demands, but on the heels of significant legislative victories secured earlier this year, demonstrating that their persistent voices are having a tangible impact. The three-day summit, the largest of its kind, served as both a rallying cry for future action and a powerful testament to the community's recent successes in shaping national health priorities.

"The National Lupus Advocacy Summit serves as a powerful demonstration that the lupus community is united, persistent, passionate, and needs to be heard," said Louise Vetter, President & CEO of the Lupus Foundation of America. "Every lupus story shared helps Congress to understand the importance of protecting access to life-changing care and treatments and continuing to invest in impactful lupus research."

A Push for Funding Meets Legislative Success

At the heart of the advocates' mission was a direct appeal for robust federal investment. Their specific requests included $15 million for the Lupus Research Program at the Department of Defense (DoD), $20 million for the Centers for Disease Control and Prevention (CDC) National Lupus Patient Registry Program, and $4 million for a training and clinical trial program at the Office of Minority Health (OMH). They also joined a broader coalition in calling for $51.3 billion for the National Institutes of Health (NIH), the world's largest public funder of medical research.

These are not just numbers on a page; they represent lifelines for the estimated 1.5 million Americans living with lupus. The DoD program, for instance, focuses on high-impact research, while the CDC registry is vital for understanding who gets the disease and why it disproportionately affects women and communities of color.

Remarkably, their pleas have already found fertile ground. In February 2026, President Biden signed into law legislation that restored $10 million to the DoD's Lupus Research Program, which had been eliminated the previous fiscal year. The same legislative package included a $4 million increase for the CDC's lupus registry, bringing its funding to $14 million, and a $1 million boost for the OMH program. While the figures don't fully match the advocates' ambitious goals, they represent major wins and a reversal of prior funding cuts, signaling a renewed commitment from Congress.

This success is the result of a long-term strategy. The Lupus Foundation of America was instrumental in establishing the DoD program in 2017 and the CDC registry in 2003, and their advocacy has since secured over $157 million for federal lupus initiatives in FY 2025 alone.

The Battle Against Insurance Barriers

Beyond funding, the advocates’ second major front is the fight for timely and affordable access to care. They specifically targeted insurance practices like prior authorization and “step therapy,” which often force patients to try and fail on older, cheaper medications before their doctor-prescribed treatment is approved.

For a lupus patient, such delays are not mere inconveniences. The autoimmune disease is characterized by unpredictable flares where the immune system attacks healthy tissues, potentially causing irreversible organ damage. "When you are in a flare, waiting weeks for an insurance company to approve the medication your doctor knows you need can mean the difference between recovery and permanent kidney damage," one rheumatologist explained anonymously. Studies have shown these policies lead to worsened clinical outcomes and significant administrative burdens that take physicians away from patient care.

The advocates' push for reform coincides with federal action. A new Centers for Medicare & Medicaid Services (CMS) rule that took effect on January 1, 2026, now requires many health plans to provide faster responses to prior authorization requests for medical services. Furthermore, just this month, CMS proposed another rule to extend these streamlined processes to prescription drugs, with a public comment period open until June. The advocates on Capitol Hill used their personal stories to underscore the urgency of these reforms and to push for even stronger legislative protections, such as those included in the bipartisan Improving Seniors’ Timely Access To Care Act.

Honoring Heroes, Highlighting the Human Cost

The summit also served as a platform to honor the individuals whose work embodies the fight against lupus. Dr. Lindsey A. Criswell, Director of the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), received the Lupus Research Hero Award for her leadership in advancing the understanding of the complex disease. The Cancio-Bello Family of Miami was honored as the Barlin Family of the Year for raising over $153,000 for the Walk to End Lupus Now® after their daughter, Bethany, was diagnosed.

Perhaps most emblematic of the summit’s spirit was the recipient of the Sandra C. Raymond Advocate of the Year Award, Lynnai Jay. A lupus warrior herself, Jay has become a tireless ambassador, support group facilitator, and public speaker. Her work gives a face to the often-invisible struggles of living with lupus, a disease that takes, on average, nearly six years to diagnose from the onset of symptoms. This diagnostic odyssey leaves many patients feeling frustrated and isolated as they navigate a cascade of seemingly unrelated symptoms, from skin rashes and debilitating fatigue to joint pain and organ failure.

Jay's advocacy, like that of the hundreds who walked the halls of Congress, is a crucial part of an ecosystem of support that includes not only patients but also researchers, fundraisers, and corporate partners. The foundation acknowledged the support of companies like AstraZeneca, GSK, Biogen, and Novartis, whose backing helped make the summit possible. Their involvement highlights the multi-pronged approach required to tackle a disease that has long been shrouded in mystery, ensuring that the momentum from this year's summit will continue to build. For the thousands of advocates who made their voices heard, both in person and online, the work continues, fueled by recent victories and an unwavering resolve to solve the mystery of lupus.